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Abstract
Introduction We examined race/ethnic differences in
treatment-related job loss and the financial impact of
treatment-related job loss, in a population-based sample of
women diagnosed with breast cancer.
Methods Three thousand two hundred fifty two women
with non-metastatic breast cancer diagnosed (August 2005–
February 2007) within the Los Angeles County and Detroit
Metropolitan Surveillance Epidemiology and End Results
registries, were identified and asked to complete a survey
(mean time from diagnosis=8.9 months). Latina and
African American women were over-sampled (n=2268,
eligible response rate 72.1%).
Results One thousand one hundred eleven women (69.6%)
of working age (<65 years) were working for pay at time of
diagnosis. Of these women, 10.4% (24.1% Latina, 10.1%
African American, 6.9% White, p<0.001) reported that
they lost or quit their job since diagnosis due to breast
cancer or its treatment (defined as job loss). Latina women
were more likely to experience job loss compared to White
women (OR=2.0, p=0.013)), independent of sociodemo-
graphic factors. There were no significant differences in job
loss between African American and White women, inde-
pendent of sociodemographic factors. Additional adjust-
ments for clinical and treatment factors revealed a
significant interaction between race/ethnicity and chemo-
therapy (p=0.007). Among women who received chemo-
therapy, Latina women were more likely to lose their job
compared to White women (OR=3.2, p<0.001), however,
there were no significant differences between Latina and
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White women among those who did not receive chemo-
therapy. Women who lost their job were more likely to
experience financial strain (e.g. difficulty paying bills 27%
vs. 11%, p<0.001).
Conclusion Job loss is a serious consequence of treatment
for women with breast cancer. Clinicians and staff need to
be aware of aspects of treatment course that place women at
higher risk for job loss, especially ethnic minorities
receiving chemotherapy.
Keywords Breast cancer . Survivorship . Employment .
Racial/ethnic disparities
Introduction
Reducing racial/ethnic disparities in survivorship outcomes
for individuals with cancer is an important research priority.
Since over half of women diagnosed with breast cancer are
of working age (less than 65 years) at the time of diagnosis,
paid work and employment outcomes are a key component
of their survivorship [1–3]. Many women diagnosed with
breast cancer must undergo a complex and arduous
treatment program while negotiating work and family
responsibilities. Although some studies suggest that cancer
and its treatment does not limit a women’s ability to return
to work [1, 2, 4–8], return to work and other work
outcomes may vary by race/ethnicity [4].
Racial and ethnic minorities may be vulnerable to poor
work outcomes because they are generally diagnosed with
more advanced disease [9, 10], require more aggressive
treatment course [11–14], and have more co-morbidities
[15]. Additionally, Latina and African American women
tend to be disproportionately represented in lower paying
jobs and unsupportive employment settings [16–18].
Despite these concerns, racial/ethnic variation in work
outcomes remain understudied. The few studies that have
examined such variation have produced mixed results with
some documenting racial/ethnic differences in work out-
comes [1] and others finding no differences [8, 19]. These
studies have been limited by small samples and a lack of
diversity by socioeconomic status and race/ethnicity.
Latinas have been particularly under-studied despite their
growing proportion among breast cancer survivors [20].
Losing one’s job is perhaps the most severe work-related
consequence and may have significant social and economic
implications. Several qualitative reports have suggested that
patient’s concerns about financial matters influence their
decisions to continue paid work during cancer treatment
[21–23]. However, few studies have assessed job loss or its
financial impact in women with breast cancer [6, 19, 24–
26]. To address these issues, we used a multi-ethnic
population-based sample of women recently diagnosed
with breast cancer in Los Angeles County and Metropolitan
Detroit to examine racial/ethnic differences in job loss and
patient report of the financial impact. Specifically, we
asked: 1) What is the extent of job loss experienced by
women diagnosed with breast cancer? 2) Are there racial/
ethnic differences in job loss? 3) What clinical and
treatment factors might explain racial/ethnic differences in
job loss? and 4) Is job loss associated with financial strain?
Patients and methods
Study population
Our study sample consisted of women who were residents
of Los Angeles and County and Metropolitan Detroit
between June 2005 and February 2007. Eligibility criteria
included: 1) 20–79 years of age, 2) a primary diagnosis of
ductal carcinoma in-situ or invasive breast cancer (American
Joint commission on Cancer Stage I–III) [27], and 3) ability
to complete a questionnaire in English or Spanish. We
excluded patients who died prior to the survey in addition to
Asian women in Los Angeles because these women were
already being enrolled in other studies. African American
women in both regions were over-sampled as well as Latinas
in Los Angeles.
Sampling and data collection
Eligible patients were identified via rapid case ascertain-
ment as they were reported to the Los Angeles Cancer
Surveillance Program (LACSP) and the Metropolitan
Detroit Cancer Surveillance System (MDCSS)—the Surveil-
lance, Epidemiology, and End Results (SEER) program
registries for the metropolitan areas of Los Angeles,
California and Detroit, Michigan. In both regions, we selected
all African American women based on demographic infor-
mation from the treating hospitals. Because Latina status is
often inaccurately reported by the treating hospitals, we used a
surname-based sampling strategy to increase the representa-
tion of Los Angeles resident Latina women in the study, an
approach validated by our research team [28]. After selecting
these racial/ethnic subgroups, we selected an approximate
one-third random sample of the remaining white (non-
Spanish surnamed) patients from both regions.
After physician notification, we mailed an introductory
letter, survey materials, and a $10 cash gift to eligible
subjects. The patient survey was translated into Spanish
using a standard approach [29] and distributed to patients in
LA who were likely to be Latina. The Spanish version was
not made available to Detroit subjects because there are
very few monolingual Spanish speaking patients in the
metropolitan Detroit area. A modified version of the
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Dillman survey method was employed to encourage survey
response including: 1) a postcard reminder to non-
respondents at 2 weeks, 2) a second letter and survey at
6 weeks, and 3) a follow-up phone call at 10 weeks [30].
The study protocol was approved by the Institutional
Review Boards of the University of Michigan, the
University of Southern California, and Wayne State
University.
Of the 3252 eligible patients who were identified for
selection, 119 were excluded because they were too ill, did
not speak English or Spanish, denied having cancer, or their
physician refused contact. Study materials were then sent to
the remaining 3133 patients, however 432 (13.8%) could
not be contacted, 411 (13.1%) patients were contacted but
did not participate in the survey, and 22 (0.7%) completed
the survey but this information could not be merged to
SEER data. Thus, 2268 (72.4% overall; 72.4% for
Hispanics; 65.8% for African Americans; and 75.4% for
whites) were included in the final analytic sample (96.5%
of whom completed a self-administered questionnaire and
3.5% completed a telephone survey).
The survey information was merged to SEER data for
patients in the final sample. An analysis of non-respondents
versus respondents showed that there were no significant
differences by age at diagnosis or Hispanic ethnicity.
However, compared to respondents, non-respondents were
more likely to be African American (34.9% vs. 26.2%,
p<.001), to have never married (23.0% vs. 19.3%,
p=.010), to have stage II or III disease (43.4% vs. 40.5%,
p=.005), and to have received a mastectomy (45.4% vs.
36.8%, p=0.020).
Study measures
The main dependent variable for this study was job loss
after diagnosis of breast cancer. Job loss was defined from
two separate questions from the patient survey. Women
were asked if they quit or lost their job since diagnosis due
to breast cancer or its treatment (each with yes/no response
options). We combined reports of quitting and losing the
job to create an overall measure of job loss because: 1) the
distribution of quitting and losing the job was similar (4.3%
quit; 5.5% lost; 0.6% reported both; 89.6% reported
neither) and 2) multivariable models (with quitting vs.
losing the job as separate dependent variables) produced
comparable results in terms of both the direction and
magnitude of associations. Although we did not collect
information on the exact timing of job loss, we did ask
women if they were working during breast cancer treatment
(yes/no).
An additional dependent variable was patient percep-
tions regarding the financial strain of breast cancer. Women
were asked to indicate whether or not (yes/no) breast cancer
diagnosis or treatments resulted in various dimensions of
financial strain including: facing an inability to pay bills,
having to use savings, or to cut down on spending for a
variety of things (food and/or clothes, health care for other
family members, children activities recreational activities,
or household items. We also asked women to report the
average number of hours worked per week (full-time ≥35;
part-time <35 h). To characterize employment support, we
asked women if either paid sick leave or a flexible work
schedule was available through their employer or work at
time of diagnosis (each with a yes/no response option). We
created an employment support variable to indicate if
women had none (neither paid sick leave nor flexible work
schedule), one (either paid sick leave or flexible work
schedule) or two (both paid sick leave and flexible work
schedule) sources of employment support.
Information was also collected on sociodemographic and
treatment factors via questionnaire. Sociodemographic
factors included study site, age at the time of diagnosis,
race/ethnicity, education, income, number supported by
family income, marital status, and time from breast cancer
diagnosis to survey completion. Treatment factors included
first surgical procedure, chemotherapy, and radiation
therapy. Clinical factors were taken from the SEER record
and patient report and included breast cancer stage at
diagnosis (using American Joint Committee on Cancer
TNM Staging System for breast cancer) [27], and patient
reported number of co-morbidities (chronic bronchitis/
emphysema, heart disease, other cancer, diabetes, high
blood pressure, stroke, arthritis).
Statistical analysis
The analytic sample was restricted to women of working
age (<65 years, n=1595) who were working at the time of
breast cancer diagnosis (n=1111, 69.6%). Descriptive
statistics were used to characterize the distribution of the
study variables overall and by race/ethnicity. Population
weights were included in all analyses to account for
differential selection by race, ethnicity, and non-response.
For each racial/ethnic group we calculated site-specific (Los
Angeles; Detroit) weights as the inverse of the number of
patients in our sample divided by the number of that race/
ethnic group in the population (defined by the SEER
registry).
Bivariate associations between job loss and each of the
independent variables were tested using Wald’s Chi-square
test. To determine the factors that may explain any
observed racial/ethnic differences in job loss based on
bivariate associations, we ran a series of logistic regression
models to adjust for potential confounders and mediators.
Model 1 estimated the odds of job loss by race/ethnicity,
independent of study site, age at diagnosis, and time since
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Table 1 Sample characteristics overall and by race/ethnicity (N=1111)
N Overall Latina (N=278) African American (N=304) White (N=497) p-value
%weighted % weighted % weighted % weighted
Sociodemographic factors
Site
Detroit 513 28.2 2.6 36.6 31.0 <0.001
Los Angeles 598 71.8 97.4 63.4 69.0
Age
<45 239 19.7 28.8 25.7 16.3 <0.001
45–54 472 42.0 41.7 36.5 43.0
55–64 400 38.3 29.5 37.8 40.7
Education
H.S diploma or less 305 29.2 53.6 17.1 15.7 <0.001
Some college 426 40.7 31.1 48.4 41.8
College graduate and beyond 369 30.1 15.3 34.5 42.5
Family income
unknown 118 9.8 18.0 6.6 8.6 <0.001
<$30,000 230 15.9 36.7 24.7 8.8
$30,000–$59,999 289 24.3 23.0 33.2 22.5
$60,000+ 474 50.0 22.3 35.5 60.1
Number supported by family income
1 270 25.0 19.5 32.4 24.5 <0.001
2 371 35.0 30.0 31.7 36.8
3+ 448 40.0 50.5 35.9 38.7
Employment status
Full-time 785 75.5 74.2 82.2 74.4 0.038
Part-time 248 24.5 25.8 17.8 25.6
Paid sick leave
Yes 589 54.5 37.8 61.8 57.5 <0.001
No 522 45.4 62.2 38.2 42.5
Flexible work schedule
Yes 642 61.5 47.2 49.3 68.0 <0.001
No 469 38.5 52.8 50.7 32.0
Employment support (paid leave/flexible schedule)a
None 297 24.4 41.7 26.4 19.5 <0.001
Only one 397 35.1 31.7 36.2 35.4
Both 417 40.5 26.6 37.4 45.1
Married/domestic partner
Yes 656 61.6 63.9 40.7 65.6 <0.001
No 444 38.4 36.1 59.3 34.4
Time from diagnosis (months)b 1090 9.1 (6.0) 10.4 8.9 8.9 <0.001
Clinical/treatment factors
Number of co-morbidities
0 607 56.3 64.0 45.1 57.2 <0.001
1 314 28.2 25.2 30.0 28.6
2+ 190 15.5 10.8 24.9 14.2
Stage
0 218 20.9 19.4 21.2 21.3 0.282
I 366 33.8 29.9 30.2 35.3
II 379 31.8 37.1 36.5 29.4
III 141 13.5 13.6 12.1 14.0
Surgical procedure
Lumpectomy 758 71.6 66.2 74.7 72.3 0.137
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breast cancer diagnosis. Model 2 additionally controlled for
other sociodemographic confounding factors and potential
mediating factors were added in Model 3 (clinical and
treatment factors).
Based on prior research, [25] we examined the interplay
between race/ethnicity, chemotherapy, and employment
support (paid sick leave/flexible work schedule) in relation
to job loss. In Model 3, we tested all two interactions
between race/ethnicity, receipt of chemotherapy, and employ-
ment support factors as well as the three way interaction.
Statistically significant interactions (p<0.05) were retained in
final models. All analyses were performed using SAS
version 9.1.3 programming language.
Results
Three quarters (75.5%) were working full-time at the time
of breast cancer diagnosis and 24.5% were working part-
time; the mean age was 50.8 (SD=7.8); and 16.5%, 15.5%,
and 68.0% were Latina, African American, and White
respectively (Table 1). The majority of women were
married (61.6%), had no co-morbidities (56.3%), received
a lumpectomy (71.6%), radiation therapy (70.7%), and
chemotherapy (54.5%). Among women receiving chemo-
therapy, 64.8% of women had completed treatment and
63.9% of women receiving radiation therapy had also
completed treatment (not shown in Table 1). More than half
of women had paid sick leave (54.6%) or a flexible work
schedule (61.5%) available at the time of diagnosis and
40.5% of women had both (Table 1). The mean time from
diagnosis to survey completion was 8.9 months (range:
1 month–26 months).
Job loss after diagnosis (quitting or losing one’s job) was
reported by 10.4% of working women and among these
women, 84.6% did not work during breast cancer treatment.
Job loss was associated with race/ethnicity in bivariate
analyses (p<0.001). Latina women had the highest preva-
lence of job loss followed by African American and White
women (24.1%, 10.1%, and 6.9% respectively). There was
also racial/ethnic variation in all sociodemographic, clini-
cal, and treatment factors (excluding breast cancer stage at
diagnosis and surgical procedure). African American
women were most likely to have two or more co-
morbidities and least likely to be married. Latinas had the
lowest levels of education and income, were most likely to
receive chemotherapy, and least likely to have paid sick
leave or a flexible work schedule available through work.
Table 2 shows the adjusted odds ratios of job loss by
categories of race/ethnicity controlling for sociodemo-
graphic, clinical, and treatment factors. In initial models
adjusted for study site, age, and time from breast cancer
diagnosis. (Model 1), the relative odds of job loss (as
compared to Whites) was 4.3 [95% C.I.: 2.6–7.0] for
Latinas. There were no significant differences in job loss
between African American and White women in Model 1
(OR, 95% C.I. 1.5 [0.9–2.8]). When additional sociodemo-
graphic factors (education, income, number supported by
family income, marital status, and paid sick leave and/or
flexible work schedule) were included, the relative odds of
Table 1 (continued)
N Overall Latina (N=278) African American (N=304) White (N=497) p-value
%weighted % weighted % weighted % weighted
Mastectomy 318 28.4 33.8 25.3 27.7
Radiation therapy
Yes 769 70.7 63.7 72.4 71.7 0.021
No 320 29.3 36.3 27.6 28.3
Chemotherapy
Yes 646 54.5 66.5 55.8 51.5 0.005
No 465 45.5 33.5 44.2 48.5
Study outcome
Job loss
Yes 144 10.4 24.1 10.1 6.9 <0.001
No 967 89.6 75.9 89.9 93.1
N=32 other race/ethnicity were excluded due to limited sample size <2% missing on all covariates
Percents are weighted to account for differential selection by race/ethnicity, and non-response
a one refers to either flexible work schedule or paid sick leave available through employer
And both refers to both paid sick leave and flexible work schedule available
b means (standard deviation) reported
p-value for chi-square test of overall significance
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Table 2 Adjusted odds ratio [95% C.I] of job loss by sociodemographic, and clinical/treatment factors
Model 1 Model 2 Model 3
Site
Detroit 1.2 [0.7–2.0] 1.3 [0.7–2.3] 1.1 [0.6–2.0]
Los Angeles 1.0 1.0 1.0
Age
<45 1.0 [0.6–1.7] 1.1 [0.6–2.0] 1.1 [0.5–2.3]
45–54 0.9 [0.6–1.4] 1.0 [0.6–1.7] 1.1 [0.6–2.0]
55–64 1.0 1.0 1.0
Χ2 p-value 0.892 0.970 0.933
Race/ethnicity
Latina 4.3 [2.6–7.0] 2.2 [1.2–4.1] N/A
African American 1.5 [0.9–2.8] 0.9 [0.4–1.7]
White 1.0 1.0
Χ2 p-value <0.001 0.024 0.401
Education
H.S diploma or less 1.1 [0.6–2.3] 1.2 [0.6–2.6]
Some College 1.1 [0.6–1.9] 1.1 [0.6–2.0]
College graduate and beyond 1.0 1.0
Χ2 p-value 0.935 0.880
Income
Unknown 1.4 [0.6–3.0] 1.6 [0.7–3.7]
<$30,000 1.6 [0.8–3.3] 1.3 [0.6–3.0]
$30,000–$59,999 0.7 [0.4–1.5] 0.6 [0.3–1.2]
≥$60,000 1.0 1.0
Χ2 p-value 0.160 0.101
Employment status
Full-time 1.2 [0.7–2.0] 1.2 [0.7–2.1]
Part-time 1.0 1.0
Employment support (paid leave/flexible schedule)a
None 7.5 [3.9–14.5] 7.3 [3.6–14.9]
Only One 2.3 [1.1–4.5] 2.4 [1.1–4.9]
Both 1.0 1.0
Χ2 p-value <0.001 <0.001
Married/domestic partner
Yes 0.8 [0.4–1.4] 0.9 [0.4–1.6]
No 1.0 1.0
Stage at diagnosis
0/I 1.0 [0.5–2.0]
II/III 1.0
Number of co-morbidities
2+ 2.5 [1.3–4.9]
1 0.7 [0.4–1.3]
0 1.0
Χ2 p-value 0.003
Surgical procedure
Mastectomy 1.5 [0.8–2.7]
Lumpectomy 1.0
Radiation therapy
Yes 0.6 [0.4–1.1]
No 1.0
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job loss (as compared to Whites) were substantively
reduced to 2.2 [95% C.I: 1.2–4.1] for Latinas and remained
statistically insignificant for African Americans. In final
models (Model 3) adjusting for treatment and clinical
factors, we found a statistically significant interaction
between race/ethnicity and receipt of chemotherapy (p=
0.007). The relative odds of job loss (as compared to
Whites) was 3.8 [95% C.I: 1.7–8.2) for Latinas and 1.3
[95% C.I.: 0.5–3.3] for African Americans, among women
who received chemotherapy. However, there were no
significant differences between Latinas and Whites (OR=
0.5, 95% C.I: 0.1–1.7) or African Americans and Whites
(OR=0.3, 95% C.I.: 0.1–1.3) among women who did not
receive chemotherapy. In final models, the number of co-
morbidities, and employment support (paid sick leave/
flexible work schedule) were also significantly associated
with job loss. Women with two or more co-morbidities
were more likely to experience job loss when compared to
women with none (OR=2.5 [95% C.I.:1.3–4.9]). Women
who did not have employment support (neither paid sick
leave nor flexible work schedule) and women who had only
one source of employment support were more likely to
experience job loss as compared to women who had both
sources of support (OR=7.3 [95% C.I: 3.6–14.9 for no
source of support; OR=2.4 [95% C.I.: 1.1–4.9] for one
source of support).
The interaction between race/ethnicity and chemotherapy
is further illustrated in Fig. 1. Among women who received
chemotherapy, job loss was most prevalent in Latinas with
15.7% reporting job loss as compared to only 6.0% of
African American women and 4.7% of White women
Table 2 (continued)
Model 1 Model 2 Model 3
Chemotherapy
Yes N/A
No
Race/Ethnicity by chemotherapy
Chemotherapy
Latina 3.8 [1.7–8.2]
African American 1.3 [0.5–3.3]
White 1.0
No chemotherapy
Latina 0.5 [0.1–1.7]
African American 0.3 [0.1–1.3]
White 1.0
Χ2 p-value for interaction 0.007
Model 1: study site, age, race/ethnicity, time from breast cancer diagnosis
Model 2: Model 1+ age, education, income, number supported by income, marital status, full-time employment, employment support (paid leave/
flexible schedule);
Model 3: Model 2+ number of co-morbidities, breast cancer stage, surgical procedure, radiation therapy, chemotherapy <2% missing on all
covariates
Χ2 represents the p-value for the chi-square test for overall significance between job loss and categorical variables with more than two levels
a one refers to either flexible work schedule or paid sick leave available through employer
And both refers to both paid sick leave and flexible work schedule available
3.7
15.7
2.6
6
7.5
4.7
0
5
10
15
20
No ChemotherapyChemotherapy
ad
jus
ted
 pe
rc
en
t 
 Latina  African American  White
Fig. 1 Adjusted percent job loss by race/ethnicity and chemotherapy.
Model includes: age, race/ethnicity, chemotherapy, race/ethnicity*che-
motherapy interaction term, education, family income, number
supported by family income, full-time employment, employment
support (paid sick leave/flexible work schedule), marital status, time
from breast cancer diagnosis, number of co-morbidities, breast cancer
stage, surgical procedure, receipt of radiation therapy. p-value for
interaction between race/ethnicity and receipt of chemotherapy p=
0.007
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(independent of sociodemographic, treatment, and clinical
factors). However, among women who did not receive
chemotherapy, there were minimal differences in job loss
across racial/ethnic groups (7.5%, 3.7%, and 2.6% among
White, Latina, and African American women respectively)
and no statistically significant differences between Latinas
and White women or African American and White women.
In investigating the interplay between race/ethnicity, receipt
of chemotherapy, and employment support (paid sick leave/
flexible work schedule), we found no statistically significant
interactions between employment support and race/ethnicity
or employment support and chemotherapy. The three way
interaction between race/ethnicity, employment support, and
receipt of chemotherapy was also not statistically significant
(all p’s >0.10)
Job loss was highly associated with most financial strain
measures (except use of savings) even after adjusting for
sociodemographic, clinical, and treatment factors (Fig. 2).
Women who experienced job loss compared to women who
did not, more often reported that they could not make credit
card payments or other bills (27.0% vs. 10.9%), had to cut
down on purchasing food and clothing (57.5% vs. 31.6%),
and had to cut down on general expenses (76.4% vs. 52.8%).
The only racial/ethnic differences in financial strain was for
difficulty paying bills (p=0.005). African American women
reported having more difficulty paying bills as compared to
Whites after adjusting for sociodemographic, clinical, and
treatment related factors (OR [95% C.I.]: 2.2 [1.3–3.6]).
Discussion
This study examined racial and ethnic differences in
treatment-related job loss in a diverse population-based
sample of working-aged women recently diagnosed with
breast cancer. We found that 10.4% of women who were
working for pay at the time of diagnosis reported job loss at
the time of survey completion (~9 months after diagnosis).
Importantly, there were substantial racial/ethnic differences
in job loss in the context of the treatment experience.
Among patients who received chemotherapy, Latina women
were more likely to lose their job after diagnosis than women
of other racial/ethnic groups but this was not observed for
women who did not receive chemotherapy. These findings
were observed after controlling for sociodemographic, clini-
cal, and treatment factors.
Prior research on paid work outcomes related to breast
cancer have generally been reassuring regarding women’s
ability to return to work after diagnosis and treatment for
breast cancer [1, 2, 4–6, 8, 25]. Yet we are unaware of any
studies that have specifically evaluated racial/ethnic differ-
ences in treatment-related job loss. Moreover, these studies
have been limited by low power and insufficient represen-
tation of ethnic minorities. We contribute to a growing body
of research on breast cancer and paid work outcomes by
focusing on African American and Latina women in a
population-based sample with sufficient representation of
these women. A previous paper by our research team
described patterns and correlates of missed paid work
during the breast cancer treatment period in a similar patient
sample [25]. Some missed work was commonly observed
(24% missed more than 1 month) after diagnosis, and
missed work was highly associated with complexity of
treatment and level of employment support (paid sick leave/
flexible work schedule). African American and Latina
women were more likely than Whites to miss more work
days as were women who received aggressive treatment
(mastectomy and chemotherapy) or were in unsupportive
employment settings (no paid sick leave, no flexible work
schedule).
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Fig. 2 Patient report of the
financial impact of breast can-
cer by job loss categories, p-
values: savings (p=0.946); all
else (p<0.001), X-axis repre-
sents patient reports of experi-
encing each type of financial
strain. Model adjusts for age,
time from initial diagnosis, race/
ethnicity, education, income,
number supported by income,
marital status, breast cancer
stage, number of co-morbidities,
surgical treatment, receipt of
radiation therapy, and receipt of
chemotherapy. <2% missing
data on all covariate
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In contrast, this analysis showed that treatment-related
job loss was much less frequent (10.4%) than missed work.
We also found that there was an interaction between race/
ethnicity and receipt of chemotherapy such that racial/
ethnic differences in job loss were only statistically
significant for women who received chemotherapy in fully
adjusted models. Latina women within this context were
particularly vulnerable to job loss, independent of being in
supportive employment settings (having paid sick leave and
a flexible work schedule). Latinas may be at particular risk
for job loss because they may have more difficulty
navigating the health care system and in turn balancing
work and treatment [18, 31, 32]. Additionally, this
vulnerability may be due to language barriers and unmea-
sured socioeconomic and employment factors (more isolated
work settings, multiple employers, or temporary employ-
ment) [31, 32].
Strengths of this study include the use of a multi-ethnic
population-based sample. We also obtained information on
a comprehensive set of sociodemographic, clinical, and
treatment factors. Some limitations to our study also merit
comment. Although we have a large study and over-
sampled for Latina and African American women, we had
limited power to detect small differences in job loss due to
the low prevalence of job loss in the study population.
Additionally, the cross-sectional design of our study limits
inferences on causal relationships between breast cancer
treatments on job loss. Patient report of experiences such as
job loss and employment accommodations may be subject
to recall bias, which may have resulted in an under or over-
estimate of experiences with job loss. However, we
interviewed women an average of 9 months post cancer
diagnosis and we have no apriori reason to believe that
recall bias differs by race/ethnicity. Finally, we did not have
objective measures of employment support and did not
measure a comprehensive set of employment support
factors. Some women who lost their jobs may have
indicated their employment settings were unsupportive,
irrespective of the actual conditions.
Our results have important implications for clinical
policy and future research. Because maintaining a healthy
and satisfying work life may prevent financial strain and
social isolation, doing so is an important issue for many
women with a new diagnosis of cancer. Clinicians and staff
need to be aware of the potential for job loss especially in
ethnic minority breast cancer patients who receive a
recommendation for chemotherapy. For these women
balancing treatment and work may be particularly difficult
even in supportive employment settings. Interventions
delivered at the practice-level should encourage clinicians
and staff to discuss job demands with patients and offer
treatment scheduling options and symptom management
strategies to help women balance cancer and work. Future
research is needed to examine the long-term consequences
of treatment-related job loss across the continuum of care
and into the survivorship period.
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